» Articles » PMID: 26438752

Payment Reform Pilot In Beijing Hospitals Reduced Expenditures And Out-Of-Pocket Payments Per Admission

Overview
Specialty Health Services
Date 2015 Oct 7
PMID 26438752
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

In 2009 China announced plans to reform provider payment methods at public hospitals by moving from fee-for-service (FFS) to prospective and aggregated payment methods that included the use of diagnosis-related groups (DRGs) to control health expenditures. In October 2011 health policy makers selected six Beijing hospitals to pioneer the first DRG payment system in China. We used hospital discharge data from the six pilot hospitals and eight other hospitals, which continued to use FFS and served as controls, from the period 2010-12 to evaluate the pilot's impact on cost containment through a difference-in-differences methods design. Our study found that DRG payment led to reductions of 6.2 percent and 10.5 percent, respectively, in health expenditures and out-of-pocket payments by patients per hospital admission. We did not find evidence of any increase in hospital readmission rates or cost shifting from cases eligible for DRG payment to ineligible cases. However, hospitals continued to use FFS payments for patients who were older and had more complications than other patients, which reduced the effectiveness of payment reform. Continuous evidence-based monitoring and evaluation linked with adequate management systems are necessary to enable China and other low- and middle-income countries to broadly implement DRGs and refine payment systems.

Citing Articles

Diagnosis-Related Group-Based Financing of Gynecologic Oncology Clinics: A Systematic Review.

Titopoulou A, Vavoulidis E, Margioula-Siarkou C, Margioula-Siarkou G, Almperis A, Petousis S Healthcare (Basel). 2025; 13(4).

PMID: 39997224 PMC: 11855615. DOI: 10.3390/healthcare13040349.


Impact of a new case-based payment scheme on volume distribution across public hospitals in Zhejiang, China: does 'Same disease, same price' matter.

Yu M, Liu J, Zhang T Int J Equity Health. 2025; 24(1):11.

PMID: 39810154 PMC: 11730486. DOI: 10.1186/s12939-025-02375-9.


Temporal trends in gender, etiology, severity and outcomes of acute pancreatitis in a third-tier Chinese city from 2013 to 2021.

Huang Y, Qiu M, Pan S, Zhou Y, Huang X, Jin Y Ann Med. 2024; 57(1):2442073.

PMID: 39699078 PMC: 11660302. DOI: 10.1080/07853890.2024.2442073.


The Impact of a New Case-Based Payment System on Quality of Care: A Difference-in-Differences Analysis in China.

Zhang X, Qian M, Yan J, Wang R, Lyu D, Ying X Risk Manag Healthc Policy. 2024; 17:3113-3124.

PMID: 39676828 PMC: 11646386. DOI: 10.2147/RMHP.S488825.


How significant is cost-shifting behavior under the diagnosis intervention packet payment reform? Evidence from the coronary heart disease market.

Tan H, Zhang X, Bi S, Chen Y, Guo D Front Public Health. 2024; 12:1431991.

PMID: 39635214 PMC: 11614845. DOI: 10.3389/fpubh.2024.1431991.